MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at three upcoming virtual investor conferences in September.
Presentation Details:
Event: H.C. Wainwright 23rd Annual Global Investment Conference
Date: Monday, September 13, 2021
Time: On-demand beginning at 7:00 a.m. ET
Event: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Tuesday, September 21, 2021
Time: 11:35 a.m. ET
Event: Cantor Fitzgerald Global Healthcare Conference
Date: Wednesday, September 29, 2021
Time: 10:00 a.m. ET
Live webcasts from the three presentations will be accessible from the Investors page of Galera’s website, investors.galeratx.com. Following the events, archived webcasts will be available on the Galera website for 30 days.
About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer. Galera’s lead product candidate is avasopasem manganese (avasopasem, or GC4419), a selective small molecule dismutase mimetic in late-stage development to reduce the incidence and...
Read Full Story: https://www.biospace.com/article/releases/galera-to-present-at-three-upcoming-investor-conferences-in-september-2021/
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.